The new GENEROUS model could reduce what federal and state Medicaid programs pay for certain brand-name drugs. But it does not mean every prescription—or every senior’s pharmacy bill—will immediately become cheaper.
Published: September 21, 2026
President Donald Trump announced on September 18 that every state will participate in a new Medicaid prescription-drug pricing initiative. The announcement is significant, but an important detail deserves clarification: according to the Centers for Medicare & Medicaid Services (CMS), all 50 state Medicaid programs, along with Washington, D.C., and Puerto Rico, have applied to participate in the GENEROUS model. State agencies have until September 30, 2026, to finalize their applications.
For older Americans, the main question is simple: Will this lower the amount I pay at the pharmacy?
The honest answer is: possibly for some Medicaid beneficiaries over time, but not automatically—and not for everyone. The program is designed first to lower the net prices paid by Medicaid, rather than to guarantee an immediate reduction in every enrollee’s copayment.
What is the GENEROUS model?
GENEROUS stands for GENErating cost Reductions fOr U.S. Medicaid. It is a five-year, voluntary CMS model launched in January 2026.
Under the model, participating pharmaceutical manufacturers provide additional rebates to state Medicaid programs. Those rebates are intended to bring Medicaid’s net cost for selected medicines closer to the lower prices paid in certain other high-income countries, including Canada, France, Germany, Italy, Japan, Switzerland, Denmark, and the United Kingdom.
The model works through the existing Medicaid Drug Rebate Program. Instead of changing the price printed on a prescription receipt, a manufacturer generally pays a supplemental rebate to the state after Medicaid covers an eligible drug. CMS monitors those payments and shares in the savings because Medicaid is jointly funded by the federal government and the states.
More than two dozen pharmaceutical companies have entered drug-pricing agreements with the administration, according to Reuters. CMS says agreements involving manufacturers such as AstraZeneca, Pfizer, and EMD Serono are expected to feed into the GENEROUS model after final terms are completed.
How much could the program save?
The White House Council of Economic Advisers estimates that the pricing initiative could save approximately $64.2 billion over 10 years—about $27.6 billion for state governments and $36.6 billion for the federal government.
That figure is a projection, not a guaranteed amount. Actual savings will depend on several factors, including:
- Which manufacturers complete agreements with CMS
- Which medicines each state chooses to include
- How many Medicaid patients use those medicines
- The size of the international-price rebates
- How the new rebates compare with discounts states already receive
Medicaid already obtains substantial drug rebates under federal law, and many states negotiate additional discounts. Therefore, the financial effect will vary by drug and by state.
Does the plan cover every prescription?
No. The model does not automatically reduce the price of every medicine.
CMS says states may decide which eligible outpatient drugs from participating manufacturers they want to include. The model focuses on single-source and innovator multiple-source drugs—categories that generally include brand-name medications—offered by manufacturers that voluntarily participate.
In exchange for the lower net prices, participating states must adopt standardized coverage criteria negotiated by CMS and each manufacturer. These rules may address matters such as prior authorization or the medical conditions for which a drug is covered.
Standardized rules could make coverage more consistent across participating states. However, patients will still need to check whether a specific medicine is covered, whether prior approval is required, and whether a preferred alternative must be tried first.
What does this mean for seniors with Medicaid?
For older adults enrolled in Medicaid, the program may have two possible benefits.
First, lower net drug costs could make it easier for a state to cover certain high-cost medicines. CMS says the model may improve access to participating drugs, although the exact effect will depend on each state’s choices and coverage policies.
Second, savings could reduce pressure on state Medicaid budgets. That may help states preserve health services or direct funds to other needs, but there is no guarantee that projected savings will be transferred directly to beneficiaries or used for a particular program.
Many Medicaid beneficiaries already pay little out of pocket for covered prescriptions. For those individuals, the most visible change may be improved access to a medicine rather than a much lower copayment.
Medicaid is not the same as Medicare
This distinction is especially important for huutri.org readers.
Medicaid is a joint federal-state program for eligible people with limited income and resources, including some older adults and people with disabilities. Medicare is federal health insurance primarily for people age 65 and older and certain younger people with disabilities.
If you have Medicare only, this Medicaid pricing announcement does not automatically change your Medicare Part D formulary, deductible, copayments, or coinsurance.
If you have both Medicare and Medicaid, often called being “dually eligible,” Medicare Part D generally provides your outpatient prescription-drug coverage. Medicaid may help with other medical costs and services. Therefore, do not assume that the GENEROUS model will immediately change the amount you pay under your Part D plan.
What should readers do now?
Most beneficiaries do not need to file a new application solely because of this announcement. However, these practical steps may help:
- Do not stop or change a medication on your own. Continue taking it as prescribed unless your doctor advises otherwise.
- Watch for notices from your state Medicaid agency or health plan. Coverage rules and participating drugs may vary by state.
- Ask before filling an expensive new prescription. Confirm whether the drug is covered, whether prior authorization is needed, and what your copayment will be.
- If you have Medicare, check your Part D or Medicare Advantage drug plan. The Medicaid announcement by itself does not revise your Medicare plan’s formulary.
- Ask for help if your income is limited. Your state may offer Medicaid or a Medicare Savings Program that can help pay Medicare premiums and, in some cases, other out-of-pocket costs.
The bottom line
The nationwide response gives the GENEROUS model broad potential reach. If the applications and manufacturer agreements are completed as planned, Medicaid programs could pay less for selected brand-name drugs and may be able to expand access to some medications.
Still, this is not an across-the-board retail price cut. Participation by manufacturers is voluntary, states choose eligible drugs, standardized coverage rules apply, and the projected $64.2 billion represents estimated government savings over a decade—not a direct payment to patients.
For senior readers, the most important step is to identify which program pays for your prescriptions—Medicaid, Medicare Part D, or another plan—and confirm coverage before assuming your medication cost has changed.
This article is for general educational purposes and does not replace advice from a state Medicaid agency, Medicare, a health plan, pharmacist, or qualified benefits counselor.
Sources